De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Protagonist Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Protagonist Therapeutics is de winst gegroeid met een gemiddeld jaarlijks percentage van 13.5%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 66.5% per jaar. Het rendement op eigen vermogen van Protagonist Therapeutics is 31.4%, en het heeft een nettomarge van 53.3%.

Belangrijke informatie

13.5%

Groei van de winst

23.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	66.5%
Rendement op eigen vermogen	31.4%
Nettomarge	53.3%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21

Protagonist EPS beats by $0.03, beats on revenue

May 04

Opbrengsten en kosten

Hoe Protagonist Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:PTGX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	319	170	40	127
31 Mar 24	315	162	40	126
31 Dec 23	60	-79	33	120
30 Sep 23	0	-140	32	121
30 Jun 23	0	-138	31	116
31 Mar 23	1	-140	30	117
31 Dec 22	27	-127	32	126
30 Sep 22	35	-130	32	135
30 Jun 22	45	-133	33	146
31 Mar 22	47	-122	32	138
31 Dec 21	27	-126	27	126
30 Sep 21	24	-108	25	107
30 Jun 21	27	-81	23	86
31 Mar 21	31	-70	20	80
31 Dec 20	29	-66	19	75
30 Sep 20	26	-65	18	71
30 Jun 20	17	-73	17	76
31 Mar 20	2	-83	17	71
31 Dec 19	0	-77	16	65
30 Sep 19	0	-74	15	63
30 Jun 19	2	-66	15	54
31 Mar 19	22	-45	14	57
31 Dec 18	31	-39	14	59
30 Sep 18	40	-28	13	57
30 Jun 18	43	-24	12	56
31 Mar 18	31	-31	12	50
31 Dec 17	20	-37	12	46
30 Sep 17	9	-45	11	43
30 Jun 17	0	-48	10	38
31 Mar 17	0	-40	9	31
31 Dec 16	0	-38	7	26
30 Sep 16	0	-32	5	21
30 Jun 16	0	-28	4	19
31 Mar 16	0	-24	4	15
31 Dec 15	0	-15	3	12

Kwaliteitswinsten: PTGX heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: PTGX is in het verleden winstgevend geweest.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: PTGX is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 13.5% per jaar laten groeien.

Versnelling van de groei: PTGX is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.

Winst versus industrie: PTGX is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs -sector ( 0.5% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 31.4% ) van PTGX wordt als hoog beschouwd.

Protagonist Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.43 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings released: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Protagonist Therapeutics, Inc. Announces Publication of Phase 1 Clinical Data on JNJ-2113 in the Journal

Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Advisor, Effective August 1, 2024

Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control

Investor sentiment improves as stock rises 16%

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

CEO, President notifies of intention to sell stock

Executive VP & Chief Financial Officer recently sold US$378k worth of stock

Executive VP & Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

CEO, President notifies of intention to sell stock

Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Consensus revenue estimates increase by 102%

Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director

Chief Development Officer exercised options to buy US$282k worth of stock.

Consensus revenue estimates increase by 250%

New minor risk - Profitability

Consensus revenue estimates fall by 30%

Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director

Price target increased by 7.3% to US$39.00

Protagonist Therapeutics, Inc., Annual General Meeting, May 27, 2024

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Price target increased by 9.1% to US$37.83

Consensus revenue estimates increase by 100%

Protagonist Reports Positive Results from Phase 1 and Pre-Clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.43 loss in 1Q 2022)

Consensus revenue estimates fall by 51%

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Full year 2022 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor

Insider exercised options to buy US$812k worth of stock.

Insufficient new directors

Third quarter 2022 earnings released: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021)

Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer

Price target decreased to US$34.40

CEO, President exercised options to buy US$187k worth of stock.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

Consensus revenue estimates increase by 28%

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Price target decreased to US$48.29

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$52.00

Insufficient new directors

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

CEO, President exercised options to buy US$680k worth of stock.

Protagonist Therapeutics, Inc., Annual General Meeting, May 26, 2022

Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Protagonist Is Still Being Undervalued Like There's Real Risk

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data

Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.21 loss in 3Q 2020)

CEO, President exercised options to buy US$720k worth of stock.